Development of Pharmaceutical Industry in Belarus

The holding company Belpharmprom was established in line with Belarus president decree No.258 of 25 July 2017 in order to improve the system of administration of the national pharmaceutical industry.
Pharmaceutical industry

The holding company is run by Managing Company of the Holding Company Belpharmprom. The holding company comprises eight organizations, including six manufacturers of medications, one research organization, and one manufacturer of medical goods. The holding company cooperates with 24 pharmaceutical organizations of various types of ownership and departmental affiliation as well as three manufacturers of medical products. The pharmaceutical industry of the Republic of Belarus develops dynamically: while there were 25 manufacturers of medications in 2012, the number rose to 41 in 2019.

The share of medications made by Belpharmprom enterprises in the country’s total output stands at 61.5%.

In 2019 the output of pharmaceutical products totaled Br1,284.8 million, five times as much as in 2012 in actual prices.

Belpharmprom enterprises account for about 90% of the country’s export of medications.

Belpharmprom’s pharmaceutical products are exported to 36 countries. The main target markets are the Russian Federation, Kazakhstan, Ukraine, and Azerbaijan.

Pharmaceutical enterprises are upgraded and retooled on schedule in order to bolster the competitive ability of Belarusian medications. In 2012-2018 the industry implemented 33 investment projects with the volume of investments in excess of $250 million.

Work is in progress to certify the commercial production of medications and pharmaceutical substances for compliance with Good Manufacturing Practices (GMP) of Belarus, countries of the European Union, PIC/S, and the U.S. Food and Drug Administration. About 90% of all the manufacturing lines of Belpharmprom enterprises have been certified already. Certificates to confirm compliance with GMP-PIC/S standards of Ukraine and GMP-EU standards of Romania have been acquired.

Some 5,600 product titles of medications and pharmaceutical substances have been registered in Belarus, including over 1,600 ones of Belarusian make: 1,578 generic ones, 82 original ones, and 22 innovative ones. They belong to different pharmacotherapeutic groups: antitumor drugs, drugs for the treatment of cardiovascular diseases, antifungal drugs, antiviral and antibacterial drugs as well as drugs for the treatment of diseases of the musculoskeletal system, digestive tract, metabolism, and other ones.